Drug Profile
AG 019
Alternative Names: AG019Latest Information Update: 18 Jan 2022
Price :
$50
*
At a glance
- Originator ActoBio Therapeutics
- Developer ActoBio Therapeutics; Precigen Inc
- Class Antihyperglycaemics; Bacteria; Gene therapies; Immunotherapies; Insulins; Interleukins; Peptides
- Mechanism of Action Gene transference; Interleukin-10 expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Type 1 diabetes mellitus
Most Recent Events
- 12 Jan 2022 Precigen plans to initiate discussions with the US FDA and European Medicines Agency (EMA) for phase II/III clinical trial design for AG 019 in Type 1 diabetes mellitus
- 13 Oct 2021 Precigen Actobio completes a phase Ib/II trial in Type 1 diabetes mellitus in USA and Belgium (NCT03751007)
- 09 Aug 2021 Precigen plans clinical trial for AG 019 (Prolong treatment) (PO)